Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
暂无分享,去创建一个
Michael Pryszlak | J. Javier Hernandez | Michael Pryszlak | Lindsay Smith | Connor Yanchus | Naheed Kurji | Vijay M. Shahani | Steven V. Molinski | V. Shahani | Naheed Kurji | C. Yanchus | J. J. Hernández | Lindsay Smith | J. Javier Hernandez | Vijay M. Shahani | Steven V. Molinski
[1] Ka-Lok Ng,et al. In silico identification of potential targets and drugs for non-small cell lung cancer. , 2014, IET systems biology.
[2] A. Godwin,et al. Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor , 2014, Molecular Cancer Therapeutics.
[3] M. Shen,et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma , 2016, Clinical Cancer Research.
[4] Laura Bennett,et al. The next steps. , 2003, BMJ.
[5] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[6] Pan Pantziarka,et al. Repurposing Drugs in Oncology: Next Steps. , 2017, Trends in cancer.
[7] Pan Pantziarka,et al. The Repurposing Drugs in Oncology (ReDO) Project , 2014, Ecancermedicalscience.
[8] M. Wong,et al. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug , 2015, PloS one.
[9] M. Wong,et al. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma , 2017, Chemical biology & drug design.
[10] Kai Hung Tiong,et al. DeSigN: connecting gene expression with therapeutics for drug repurposing and development , 2017, BMC Genomics.
[11] Tahir Ali Chohan,et al. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. , 2014, Current medicinal chemistry.
[12] Matthias Gottwald,et al. Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data , 2016, Frontiers in pharmacology.
[13] B. Soares,et al. Trifluoperazine for schizophrenia. , 2004, The Cochrane database of systematic reviews.
[14] N. Sood,et al. Dynamic cost-effectiveness of oncology drugs. , 2012, The American journal of managed care.
[15] C. Chong,et al. New uses for old drugs , 2007, Nature.
[16] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[17] Richard B. Smith,et al. Repositioned drugs: integrating intellectual property and regulatory strategies , 2011 .
[18] H. Kantarjian,et al. Cancer Drugs: An International Comparison of Postlicensing Price Inflation. , 2017, Journal of oncology practice.
[19] Chi-Ying F. Huang,et al. From NPC Therapeutic Target Identification to Potential Treatment Strategy , 2010, Molecular Cancer Therapeutics.
[20] Y. Miyoshi,et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] K. Leung,et al. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma , 2015, Molecular medicine reports.
[22] V. Sukhatme,et al. Drug repurposing in oncology—patient and health systems opportunities , 2015, Nature Reviews Clinical Oncology.
[23] C. Telleria. Drug Repurposing for Cancer Therapy. , 2012, Journal of cancer science & therapy.
[24] C. Russell,et al. Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma , 2006, Cancer investigation.
[25] Amy Maxmen,et al. Busting the billion-dollar myth: how to slash the cost of drug development , 2016, Nature.
[26] Shuangping Zhao,et al. An Integrated Bioinformatics Approach Identifies Elevated Cyclin E2 Expression and E2F Activity as Distinct Features of Tamoxifen Resistant Breast Tumors , 2011, PloS one.
[27] Chi-Ying F. Huang,et al. Using computational strategies to predict potential drugs for nasopharyngeal carcinoma , 2013, Head & neck.
[28] Three-way street , 1990 .
[29] David A. Flockhart,et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[30] Cheng-Yan Kao,et al. Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma , 2011, PloS one.
[31] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[32] A. Śliwińska,et al. Metformin in cancer prevention and therapy. , 2014, Annals of translational medicine.
[33] Chi-Ying F. Huang,et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. , 2012, American journal of respiratory and critical care medicine.
[34] Tudor I Oprea,et al. Computational and Practical Aspects of Drug Repositioning. , 2015, Assay and drug development technologies.
[35] Harish Dureja,et al. Product lifecycle management through patents and regulatory strategies , 2013 .
[36] Tudor I. Oprea,et al. Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.
[37] Zhiyong Lu,et al. A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..
[38] Nilay D. Shah,et al. Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions , 2013, Journal of managed care pharmacy : JMCP.
[39] Atul J. Butte,et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma , 2016, Oncotarget.
[40] Deric M. Park,et al. Identification of repurposed small molecule drugs for chordoma therapy , 2013, Cancer biology & therapy.
[41] D. Hughes,et al. Affordable orphan drugs: a role for not‐for‐profit organizations , 2017, British journal of clinical pharmacology.
[42] Deepak K Rajpal,et al. Applications of Connectivity Map in drug discovery and development. , 2012, Drug discovery today.
[43] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[44] R. Handfield,et al. Insurance companies' perspectives on the orphan drug pipeline. , 2013, American health & drug benefits.
[45] J. Dunn,et al. How drug life-cycle management patent strategies may impact formulary management. , 2017, The American journal of managed care.
[46] P. Pantziarka. Scientific advice — is drug repurposing missing a trick? , 2017, Nature Reviews Clinical Oncology.
[47] Terukazu Nakamura,et al. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. , 2014, Urologic oncology.